Quantitative measurement of FMRP in blood platelets as a new screening test for fragile X syndrome
|
|
- Gregory Buck McCoy
- 5 years ago
- Views:
Transcription
1 Clin Genet 2012: 82: Printed in Singapore. All rights reserved Short Report 2011 John Wiley & Sons A/S CLINICAL GENETICS doi: /j x Quantitative measurement of FMRP in blood platelets as a new screening test for fragile X syndrome Lessard M, Chouiali A, Drouin R, Sébire G, Corbin F. Quantitative measurement of FMRP in blood platelets as a new screening test for fragile X syndrome. Clin Genet 2012: 82: John Wiley & Sons A/S, 2011 The fragile X syndrome usually results from CGG repeats expansion and methylation of the FMR1 gene leading to the absence of expression of its encoded protein, fragile X mental retardation protein (FMRP). Therefore, its diagnosis is traditionally based on the detection of these molecular alterations. As an alternative, FMRP-based screening methods have been proposed over the years. Most of them are based on immunohistochemistry analyses applied to a restricted number of lymphocytes (100) or hair roots (10 20) with limited diagnosis potential. In this study, we describe a truly quantitative approach using a new model, the blood platelet, which can be recovered easily with very high purity (99.9%). FMRP levels in platelets were first measured in a control population (n = 124) and reference values were established. FMRP measurements were also performed in confirmed fragile X subjects. Receiver operating characteristic curve analysis has shown that our test can easily discriminate fragile X males and females from controls (area under curve, AUC = 0.948). Cognitive functions were also assessed in these individuals using age-specific Wechsler Intelligence Scales for Children and the Vineland Adaptive Behavior Scales. A proportional relationship between FMRP levels, intelligence quotient and adaptive behavior was observed among fragile X individuals, suggesting that our test would be able to detect fragile X cases and may predict cognitive functions. Conflict of interest Nothing to declare. M Lessard a, A Chouiali a, R Drouin b,gsébire b and F Corbin a a Department of Biochemistry, and b Department of Pediatrics, Faculty of Medicine and Health Sciences, Université de Sherbrooke, Sherbrooke, Québec, Canada Key words: blood platelets cognitive functions diagnosis FMRP fragile X syndrome reference values Corresponding author: François Corbin, Department of Biochemistry, Faculty of Medicine and Health Sciences, Université de Sherbrooke, 3001, 12e Ave Nord, Sherbrooke, Québec J1H 5N4, Canada. Tel.: x15801; fax: ; francois.corbin@usherbrooke.ca Received 23 June 2011, revised and accepted for publication 7 October 2011 The fragile X syndrome is the most common form of inherited intellectual disability (ID) (1, 2). In most cases, the disease is caused by CGG repeats expansion within the 5 untranslated region of the fragile X mental retardation 1 (FMR1 ) gene. More precisely, the full mutation is characterized by more than 200 CGG repeats along with the methylation of a CpG island upstream of the FMR1 gene. This methylation blocks the expression of the gene resulting in the absence (males) or reduction (females) of fragile X mental retardation protein (FMRP) expression (3). The altered level of FMRP is believed to be responsible for the clinical manifestations of the syndrome. However, point mutations or deletions in the FMR1 gene also lead to the same clinical features (4). Global intellectual functioning is usually assessed by age-specific Wechsler scales that provide the intelligence quotient (IQ). IQ amongst fragile X individuals is highly variable where most affected males have a moderate ID (IQ from to 50 55) while only 25 30% of the females are intellectually impaired (IQ < 70) (5, 6). ID may also give significant limitations 472
2 New screening test for fragile X syndrome in adaptive behavior that can be measured using the Vineland Adaptive Behavior Scales (VABS) (7, 8). The VABS is a well-standardized test and measures communication, socialization and daily living skills. VABS scores are typically higher in females than in males while being variable within each gender (7). The presence of a normal allele which has the ability to produce FMRP would be responsible for the less severe phenotype observed in females. Molecular approach using Southern blot and polymerase chain reaction (PCR) analyses, remains the gold standard confirmatory test for fragile X syndrome (9). Because methylation of the FMR1 gene leads to the absence or reduction in FMRP expression, FMRPbased screening strategies have been proposed (10 14). Most of these methods are based on the detection of FMRP-positive lymphocytes or hair roots following immunochemistry with an anti-fmrp antibody. They have shown relationships between FMRP expression and cognitive abilities (10 12). However, these methods have limited sensibility to detect fragile X females and mosaics. In this study, we developed a new quantitative measurement method for FMRP levels in blood platelet extracts. For the first time, reference values were determined for a control population and showed to be higher as compared to our fragile X group. Additionally, a relationship between FMRP and cognitive functions was shown, suggesting that this method would be a useful diagnostic and prognostic tool. Materials and methods Research subjects Healthy controls and confirmed fragile X subjects (minors and adults) were recruited according to the research protocol approved by the ethics committee of our institution (08-128). Isolation of platelets Platelet-rich plasma was obtained from blood collected in ethylenediaminetetraacetic acid (EDTA) tubes following its centrifugation at 350 g for 10 min. Platelets were counted with an automated fluorescent flow cytometer then washed with PBS supplemented with 5 mm EDTA. Whole protein extracts were prepared in 2% sodium dodecyl sulfate (SDS) sample buffer as described previously (15). FMRP quantification His-tagged purified FMRP isoform 1 (provided by Edouard W Khandjian) was quantified and used as FMRP standards for quantification purposes. Protein extracts corresponding to platelets for each subject along with known amounts of FMRP standards ranging from to 0.32 ng were loaded on a 4 12% gradient sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE). Following protein transfer, Western blot was carried out using the anti-fmrp antibody 1C3 (Chemicon, Temecula, CA) along with an infrared fluorescence-labeled (goat antimouse Alexa R Fluor 680, Invitrogen, Eugene, OR) secondary antibody. In some experiments, Western blot analyses were performed with an anti-tubulin antibody and a goat anti-rabbit Alexa R Fluor 680 secondary antibody. The Odyssey R Infrared Imaging System (LI-COR Biosciences, Lincoln, NE) was used to detect FMRP fluorescence signals from subjects and standards. Using a linear standard curve, as calculated by the included software, quantitative FMRP levels were determined for each subject. The obtained value represents an average amount of FMRP in picograms per million of platelets (pg/10 6 platelets). Cognitive evaluations Cognitive evaluations were performed on 15 males and 9 females with the fragile X syndrome by a neuropsychologist. French Canadians versions of the Wechsler Intelligence Scale for Children fourth edition (WISC-IV) was administrated to five fragile X children and the Wechsler Adult Intelligence Scale third edition (WAIS-III) to 19 adults (minimal score 40). A French Canadian version (CHU Ste-Justine) of the VABS was administered to caregivers. For each cognitive evaluation, full scale IQ as well as the Vineland Adaptive Behavior Composite (VABC) and all their respective subscales were considered (minimal score 20). Data analysis The data were analyzed with spss (version 17.0). MedCalc version was used to produce the receiver-operating characteristic (ROC) analysis. Data from inter-group were compared with Student s t-test (normal distribution) and Mann Withney s test (abnormal distribution). Relationship between FMRP and cognitive functions was analyzed with Spearman s ρ test. The data are presented with 95% confidence intervals. Results Normal distribution of platelet FMRP levels in control subjects Western blot analysis for FMRP was performed on whole cell extracts from platelets of a confirmed fragile X male and a control individual (Fig. 1a). FMRP in control platelets shows a classic protein pattern with a major band at 80 kda, as a tight doublet, and 5 6 minor bands as shown in other cells or tissues (16). These bands were not detected in a fragile X individual, thus confirming the specificity of the obtained signal (Fig. 1a). FMRP levels were determined for the first time in control individuals. As shown in Fig. 1b, data followed a normal distribution allowing parametric 473
3 Lessard et al. Fig. 1. Fragile X mental retardation protein (FMRP) levels from a control population follow a normal distribution. FMRP in platelets has a classic protein pattern which is not detected in a fragile X male. Western blot analyses were performed on platelet extract from a control and fragile X (FX) male using an anti-fmrp antibody and an anti-tubulin antibody as a loading control. FMRP levels were measured in a control population in order to establish reference values. The control group was composed of 124 subjects (61 females and 63 males) evenly distributed between 4 and 50 years of age without intellectual disability. statistical analysis. A mean value of 29.6 ± 7.5 pg/10 6 platelets was obtained that was not affected by age or gender (data not shown). Considering two standard deviations, the reference values would range from 14.6 to 44.6 pg/10 6 platelets. Within-run and between-run precision was less than 5% and 10%, respectively. Platelet s FMRP levels can discriminate fragile X syndrome subjects from controls These measured levels of FMRP in the control population were compared with those found among fragile X syndrome subjects. As expected, levels of FMRP among males with fragile X syndrome were significantly lower than controls (p < 0.001) (Fig. 2a). In fact, no signal was obtained for 12 out of 16 males whereas the highest level for the remaining four fragile X individuals was 8.6 pg/10 6 platelets. Two of these males were known to have repeat size mosaicism, explaining why FMRP expression was detected. As expected, fragile X females showed significantly higher expression levels (from 11.1 to 27.3 pg/10 6 platelets) than fragile X males, while still being inferior to those in controls (p < 0.001) (Fig. 2a). In order to determine the overall ability of our test to discriminate controls from fragile X individuals, a ROC curve analysis was carried out using data from controls Fig. 2. Fragile X mental retardation protein (FMRP) levels can discriminate fragile X syndrome subjects from healthy controls. Box-Plot analysis showing lower levels of FMRP in fragile X syndrome subjects as compared to control individuals. The fragile X group (n = 26) was composed of 10 females between 17 and 42 years of age and 16 males between 7 and 39 years. Values for males (white) and females (gray) were calculated separately. There was no statistical difference between control males and control females. Using the Mann Whitney U test, a statistical difference was observed between control and fragile X group (p < 0.001), between fragile X syndrome and control males (p < 0.001) and between control and fragile X females (p < 0.001). Also, a statistical difference was noticed between females and males with fragile X (p < 0.001). Receiver-Operating Characteristic (ROC) curve analysis illustrating the great diagnostic performance of FMRP levels measurement for the fragile X syndrome. The area under the ROC curve gave a value of A threshold value of 27.3 pg/10 6 platelets gives a sensitivity of 100% and a specificity of 61.3%. 474
4 New screening test for fragile X syndrome and all fragile X individuals. Our test yielded an area under the ROC curve of (Fig. 2b). For screening purposes with a sensitivity of 100%, the FMRP threshold value would be 27.3 pg/10 6 platelets, which has a corresponding specificity of 61.3% for both genders. Relationship between FMRP levels and IQ among fragile X syndrome individuals IQ determination in our fragile X population showed, as expected, a significantly higher IQ for females than for males and a low dispersion of IQs among subjects of each gender (Table 1b). When male and female data were combined, a significant relationship was observed between FMRP levels and full scale IQ (r s = 0.91, p < 0.01; Fig. 3a). A similar relationship was also observed between FMRP and each subscale (data not shown). Relationship between FMRP levels and adaptive behavior among fragile X syndrome individuals Similar to the IQ scale, VABC scores were significantly higher for females than for males (Table 1b). However, we observed for each gender a higher dispersion in adaptive behavior than the IQ (Table 1b). The relationship between FMRP quantification and adaptive behavior was also established. When male and female data were combined, a significant direct proportional relationship was observed between FMRP levels, VABC, communication, daily living skills and socialization domains (Fig. 3b). Considering only the male group, no significant relationship remained. For females, relationships between FMRP and VABC (r s = 0.86, p = 0.03), daily living skills (r s = 0.93, p < 0.01), socialization remain significant (r s = 0.82, p < 0.01). Therefore our results suggest that the FMRP levels quantification may predict adaptive behavior of fragile X subjects and particularly in females. Discussion Our proposed quantitative method, based on the detection of FMRP in platelets, brings many innovations to FMRP-based screening strategy for the fragile X syndrome. Platelets offer many advantages over lymphocytes since they can be recovered easily with an unmatched purity of 99.9%. They are less prone to physiological and pathological variations than lymphocytes. In contrast, lymphocytes preparation are significantly contaminated by platelets that would significantly affect total FMRP quantification by Western blot (14) or enzyme-linked immunosorbent assay (13). One cubic centimeter of whole blood can yield the five million platelets from which FMRP quantification is performed. This huge number of platelets is certainly more representative of its overall expression as compared to 100 lymphocytes (12) or hair roots (11). Moreover, our method does not require visual judgment of staining (positive/negative) Table 1. Subjects characteristics: mean age, SD and age range in the control and the fragile X group and cognitive measures statistics of fragile X syndrome subjects Group Controls (n = 124) Fragile X (n = 26) Gender Males (n = 63) Females (n = 61) Males (n = 16) Females (n = 10) Age Mean SD Range Cognitive measures Fragile X (n = 24) Males (n = 15) Females (n = 9) IQ Mean SD Range VABC Mean SD Range < Communication Mean SD Range < Daily living skills Mean SD Range < Socialization Mean SD Range < IQ, intelligence quotient; VABC, Vineland Adaptive Behavior Composite; SD, standard deviation. eliminating possible interpretation bias from the operator (10 12). Denaturation of protein extracts with SDS sample buffer is mandatory to preserve FMRP solubility and stability. In fact, no sign of protein degradation has been observed over 6 months following the storage of extracts at 80 C (data not shown). Western blot analyses based on infrared fluorescence detection are increasingly preferred over enzyme approaches particularly for quantitative purposes since they have shown greater linearity and reproducibility (17, 18). Moreover, this approach will detect other mutations (4) within the FMR1 gene substantially affecting FMRP expression of FMRP length (>2 kda) and its migration on SDS-PAGE gels. To our knowledge, this is the first study where FMRP reference values are established from a control population. Our test showed a great overall diagnostic performance (AUC = 0.948), suggesting a high potential for discriminating fragile X males and even females from healthy controls. By selecting the best threshold at 27.3 pg/10 6 platelets for screening purposes (100% of sensitivity), a remarkable specificity of 61.3% can still be reached. By comparison, the proposed threshold for the lymphocytes immunohistochemistry method has 475
5 Lessard et al. Fig. 3. Graphical representation of the relationship between fragile X mental retardation protein (FMRP) levels and cognitive functions in fragile X subjects. Relationship between full scale intelligence quotient (IQ) and FMRP levels: When males and females were combined, the nonparametric Spearman s ρ test suggests a significant relationship between FMRP levels and full scale IQ. Relationship between adaptive behavior and FMRP levels: When both genders are considered, the non-parametric Spearman s ρ test suggests a significant relationship between FMRP levels and the Vineland Adaptive Behavior Composite (VABC) and each domain of the VABS (communication, daily living skills and socialization). In females we observed a significant relationship between FMRP levels and the VABC (r s = 0.86, p = 0.03) as well as two domains; daily living skills (r s = 0.93, p < 0.013) and socialization (r s = 0.82, p < 0.01). An arbitrary value of 10 was given to individuals having a score <20. a specificity of 41% with a corresponding sensitivity of 41% (19) limiting significantly the method s usefulness in females. Intriguingly, our method detected the presence of FMRP in four fragile X males, where only two were confirmed as mosaic. All four patients had FMRP levels below 10 pg/10 6 platelets indicating a very low percentage of mosaicity. We propose that these two individuals would have a partially methylated full mutation that was not detected by Southern blot. As both, platelets and lymphocytes are derived from hematopoietic stem cells, we should not expect differences in mosaicity between these cell types. Our analysis supports a positive relationship between FMRP and cognitive evaluations (full scale IQ and VABS) when male and female data are combined. However, most of these relationships vanished when groups are analyzed separately. Interestingly, this relationship remained between FMRP levels and adaptive behavior in females. This correlation was not observed by other groups who used immonohistochemistry with lymphocytes (7, 8), which might indicate that our quantitative method is superior. As a progressive skewing X-inactivation toward the normal allele over the years has been shown in female (20), we probably obtained a higher mean level of FMRP in our older female population than expected. Therefore, recruiting additional subjects of all IQ levels especially mosaic males with higher IQs as well as younger female individuals is needed to confirm our described observations. Further research is thus required for a better understanding of these relationships within each gender. Whether their average platelet FMRP levels reflect their brain FMRP levels is unknown. Finally, if the FMRP-based strategy is used for screening, Southern blot and PCR detections of the CGG expansion will always remain the reference method to confirm classic fragile X cases and premutated carrier. We believe that our quantitative FMRP approach using platelet extracts is superior in many aspects to the previously reported methods, although still requiring additional validation in a larger population. Technically simple to perform, our method would also predict cognitive functions and could be particularly useful for genetic counseling and for optimizing the care of early diagnosed patients. Acknowledgements We are grateful to Sophie Gagnon for the cognitive assessments. We also wish to thank Sylvie Auger for technical assistance and Nathalie Guay for blood sampling. We are grateful to Edward W Khandjian for the purified FMRP recombinant protein. This work was supported by the Fonds de Recherche en Santé du Québec (FRSQ) and the Foundation of the Stars. F. C. is a Junior 1 research scholar from the FRSQ. References 1. Coffee B, Keith K, Albizua I et al. Incidence of fragile X syndrome by newborn screening for methylated FMR1 DNA. Am J Hum Genet 2009: 85: Turner G, Webb T, Wake S, Robinson H. Prevalence of fragile X syndrome. Am J Med Genet 1996: 64:
6 New screening test for fragile X syndrome 3. Pieretti M, Zhang FP, Fu YH et al. Absence of expression of the FMR-1 gene in fragile X syndrome. Cell 1991: 66: Coffee B, Ikeda M, Budimirovic DB, Hjelm LN, Kaufmann WE, Warren ST. Mosaic FMR1 deletion causes fragile X syndrome and can lead to molecular misdiagnosis: a case report and review of the literature. Am J Med Genet 2008: 146A: Chonchaiya W, Schneider A, Hagerman RJ. Fragile X: a family of disorders. Adv Pediatr 2009: 56: de Vries BB, Wiegers AM, Smits AP et al. Mental status of females with an FMR1 gene full mutation. Am J Hum Genet 1996: 58: Glaser B, Hessl D, Dyer-Friedman J et al. Biological and environmental contributions to adaptive behavior in fragile X syndrome. Am J Med Genet A 2003: 117A: Hatton DD, Wheeler AC, Skinner ML et al. Adaptive behavior in children with fragile X syndrome. Am J Ment Retard 2003: 108: Rousseau F, Heitz D, Biancalana V et al. Direct diagnosis by DNA analysis of the fragile X syndrome of mental retardation. N Eng J Med 1991: 325: Loesch DZ, Huggins RM, Hagerman RJ. Phenotypic variation and FMRP levels in fragile X. Ment Retard Dev Disab Res Rev 2004: 10: Willemsen R, Anar B, De Diego Otero Y et al. Noninvasive test for fragile X syndrome, using hair root analysis. Am J Hum Genet 1999: 65: Willemsen R, Smits A, Mohkamsing S et al. Rapid antibody test for diagnosing fragile X syndrome: a validation of the technique. Hum Genet 1997: 99: Iwahashi C, Tassone F, Hagerman RJ et al. A quantitative ELISA assay for the fragile x mental retardation 1 protein. J Mol Diagn 2009: 11: Kaufmann WE, Abrams MT, Chen W, Reiss AL. Genotype, molecular phenotype, and cognitive phenotype: correlations in fragile X syndrome. Am J Med Genet 1999: 83: Corbin F, Bouillon M, Fortin A, Morin S, Rousseau F, Khandjian EW. The fragile X mental retardation protein is associated with poly(a)+ mrna in actively translating polyribosomes. Hum Mol Genet 1997: 6: Khandjian EW, Fortin A, Thibodeau A et al. A heterogeneous set of FMR1 proteins is widely distributed in mouse tissues and is modulated in cell culture. Hum Mol Genet 1995: 4: Fogarty GB, Conus NM, Chu J, MacArthur G. Characterization of the expression and activation of the epidermal growth factor receptor in squamous cell carcinoma of the skin. Br J Dermatol 2007: 156: Wang YV, Wade M, Wong E, Li YC, Rodewald LW, Wahl GM. Quantitative analyses reveal the importance of regulated Hdmx degradation for p53 activation. Proc Natl Acad Sci U S A 2007: 104: Ramos FJ, Willemsen R. Diagnosis of the fragile X syndrome by the analysis of FMRP expression in blood and hair roots. Arch Pediatr 2003: 10: Rousseau F, Heitz D, Oberle I, Mandel JL. Selection in blood cells from female carriers of the fragile X syndrome: inverse correlation between age and proportion of active X chromosomes carrying the full mutation. J Med Genet 1991: 28:
New blood test measures levels of fragile X protein
NEWS New blood test measures levels of fragile X protein BY KELLY RAE CHI 22 SEPTEMBER 2009 1 / 8 C. Iwahashi A new molecular screen allows researchers to determine for the first time the precise amounts
More informationPopulation Screening for Fragile X Syndrome
Population Screening for Fragile X Syndrome FLORA TASSONE PH.D. DEPARTMENT OF BIOCHEMISTRY AND MOLECULAR MEDICINE AND MIND INSTITUTE UC DAVIS, CALIFORNIA USA Molecular Pathology: Principles in Clinical
More informationJournal of Medical Genetics Copyright (C) 1997 by Journal of Medical Genetics.
Journal of Medical Genetics Copyright (C) 1997 by Journal of Medical Genetics. Volume 34(11) November 1997 pp 924-926 Prenatal diagnosis of the fragile X syndrome: loss of mutation owing to a double recombinant
More informationScreening for fragile X syndrome among Brazilian mentally retarded male patients using PCR from buccal cell DNA
D.M. Christofolini et al. 448 Screening for fragile X syndrome among Brazilian mentally retarded male patients using PCR from buccal cell DNA D.M. Christofolini, M.V.N. Lipay, M.A.P. Ramos, D. Brunoni
More informationNext-generation Diagnostics for Fragile X disorders
Next-generation Diagnostics for Fragile X disorders Overview Bio-Link presents novel diagnostic technology that offers compelling clinical, technical and commercial advantages over existing tests for fragile
More informationGenetic diagnosis in clinical psychiatry: A case report of a woman with a 47,XXX karyotype and Fragile X syndrome
Eur. J. Psychiat. Vol. 23, N. 1, (31-36) 2009 Keywords: Fragile X; 47,XXX; obesity; hyperphagia; affective disorder. Genetic diagnosis in clinical psychiatry: A case report of a woman with a 47,XXX karyotype
More informationORIGINAL RESEARCH ARTICLE American College of Medical Genetics and Genomics
ORIGINAL RESEARCH ARTICLE American College of Medical Genetics and Genomics Molecular genetic testing for fragile X syndrome: laboratory performance on the College of American Pathologists proficiency
More informationA solution to limitations of cognitive testing in children with intellectual disabilities: the case of fragile X syndrome
J Neurodevelop Disord (2009) 1:33 45 DOI 10.1007/s11689-008-9001-8 A solution to limitations of cognitive testing in children with intellectual disabilities: the case of fragile X syndrome David Hessl
More informationMouse Cathepsin B ELISA Kit
GenWay Biotech, Inc. 6777 Nancy Ridge Drive San Diego, CA 92121 Phone: 858.458.0866 Fax: 858.458.0833 Email: techline@genwaybio.com http://www.genwaybio.com Mouse Cathepsin B ELISA Kit Catalog No. GWB-ZZD154
More informationalleles in high-functioning FM and PM males determined by both reference methods were also unmethylated
Clinical Chemistry 60:7 963 973 (2014) Molecular Diagnostics and Genetics Early Detection of Fragile X Syndrome: Applications of a Novel Approach for Improved Quantitative Methylation Analysis in Venous
More informationGenotype, Molecular Phenotype, and Cognitive Phenotype: Correlations in Fragile X Syndrome
American Journal of Medical Genetics 83:286 295 (1999) Genotype, Molecular Phenotype, and Cognitive Phenotype: Correlations in Fragile X Syndrome Walter E. Kaufmann, 1,2,3,4* Michael T. Abrams, 4,5 Wilma
More informationFRAGILE X MOLECULAR DIAGNOSTICS ORDERING INFORMATION. FragilEaseTM FRAGILEASETM ASSAY CHARACTERISTICS WORKFLOW. PCR Purification.
ORDERING INFORMATION FRAGILEASE ASSAY CHARACTERISTICS High and low throughput options for cost- and timeefficient analyses 96 or 1152 reactions per kit Turnaround time from DNA to report approximately
More informationJournal of Medical Genetics Copyright (C) 2002 by Journal of Medical Genetics.
Journal of Medical Genetics Copyright (C) 2002 by Journal of Medical Genetics. Volume 39(3) March 2002 pp 196-200 A single base alteration in the CGG repeat region of FMR1: possible effects on gene expression
More informationNIH Public Access Author Manuscript J Neurodev Disord. Author manuscript; available in PMC 2009 October 27.
NIH Public Access Author Manuscript Published in final edited form as: J Neurodev Disord. 2009 March 1; 1(1): 33 45. doi:10.1007/s11689-008-9001-8. A solution to limitations of cognitive testing in children
More informationNoninvasive Test for Fragile X Syndrome, Using Hair Root Analysis
Am. J. Hum. Genet. 65:98 103, 1999 Noninvasive Test for Fragile X Syndrome, Using Hair Root Analysis Rob Willemsen, 1 Burcu Anar, 1 Yolanda De Diego Otero, 1 Bert B. A. de Vries, 1 Yvonne Hilhorst-Hofstee,
More informationFragile X syndrome in children with learning difficulties and the diagnostic dilemma
Fragile X syndrome in children with learning difficulties and the diagnostic dilemma Bhagya Chandrasekara 1, Sulochana Wijesundera 2, *Hemamali Perera 3 Sri Lanka Journal of Child Health, 2016; 45(1):
More informationAna Apolónio (ARSA)& Vítor Franco (U. Évora)
1 ᶳᶵ International Early Childhood Conference Eurlyaid Annual Conference 2012 Braga, 14.09.2012 Ana Apolónio (ARSA)& Vítor Franco (U. Évora) Projecto PTDC/CPE-CED/115276/2009 Fragile X Syndrome Most common
More informationPCR testing for FMR1-related disorders at the Children s Hospital at Westmead: past and present. Dr Karen Wong
PCR testing for FMR1-related disorders at the Children s Hospital at Westmead: past and present Dr Karen Wong FMR1-related disorders Fragile X syndrome Fragile X-associated tremor/ataxia (FXTAS) Fragile
More informationFragile X Syndrome. Genetics, Epigenetics & the Role of Unprogrammed Events in the expression of a Phenotype
Fragile X Syndrome Genetics, Epigenetics & the Role of Unprogrammed Events in the expression of a Phenotype A loss of function of the FMR-1 gene results in severe learning problems, intellectual disability
More informationFEP Medical Policy Manual
FEP Medical Policy Manual Effective Date: April 15, 2018 Related Policies: 2.04.59 Genetic Testing for Developmental Delay/Intellectual Disability, Autism Spectrum Disorder, and Congenital Anomalies Genetic
More informationProduct Datasheet. EMMPRIN/CD147 Antibody (MEM-M6/1) NB Unit Size: 0.1 mg. Store at 4C. Do not freeze. Publications: 2
Product Datasheet EMMPRIN/CD147 Antibody (MEM-M6/1) NB500-430 Unit Size: 0.1 mg Store at 4C. Do not freeze. Publications: 2 Protocols, Publications, Related Products, Reviews, Research Tools and Images
More informationHuman Cathepsin D ELISA Kit
GenWay Biotech, Inc. 6777 Nancy Ridge Drive San Diego, CA 92121 Phone: 858.458.0866 Fax: 858.458.0833 Email: techline@genwaybio.com http://www.genwaybio.com Human Cathepsin D ELISA Kit Catalog No. GWB-J4JVV9
More informationIMMEDIATE HOT LINE: Effective January 6, 2014
MEDICARE COVERAGE OF LABORATORY TESTING Please remember when ordering laboratory tests that are billed to Medicare/Medicaid or other federally funded programs, the following requirements apply: 1. Only
More informationGenetic Testing for FMR1 Variants (Including Fragile X Syndrome)
Medical Policy Manual Genetic Testing, Policy No. 43 Genetic Testing for FMR1 Variants (Including Fragile X Syndrome) Next Review: February 2019 Last Review: February 2018 Effective: April 1, 2018 IMPORTANT
More informationDo women with fragile X syndrome have problems in switching attention: Preliminary findings from ERP and fmri
Brain and Cognition 54 (2004) 235 239 www.elsevier.com/locate/b&c Do women with fragile X syndrome have problems in switching attention: Preliminary findings from ERP and fmri Kim Cornish, a,b, * Rachel
More informationFragile X One gene, three very different disorders for which Genetic Technology is essential. Significance of Fragile X. Significance of Fragile X
Fragile X One gene, three very different disorders for which Genetic Technology is essential Martin H. Israel Margaret E. Israel mhi@wustl.edu meisrael@sbcglobal.net uel L. Israel Association of Genetic
More informationarticle April 2005 Vol. 7 No. 4 METHODS
article April 2005 Vol. 7 No. 4 Fragile X syndrome carrier screening in the prenatal genetic counseling setting Amy Cronister, MS 1, Miriam DiMaio, MSW 2, Maurice J. Mahoney, MD, JD 2, Alan E. Donnenfeld,
More informationFeasibility and acceptance of screening for fragile X mutations in low-risk pregnancies
European Journal of Human Genetics (1999) 7, 212 216 t 1999 Stockton Press All rights reserved 1018 4813/99 $12.00 http://www.stockton-press.co.uk/ejhg ARTICLE Feasibility and acceptance of screening for
More informationAre we Close to Solve the Mystery of Fragile X Associated Premature Ovarian Insufficiency (FXPOI) in FMR1 Premutation Carriers?
Are we Close to Solve the Mystery of Fragile X Associated Premature Ovarian Insufficiency (FXPOI) in FMR1 Premutation Carriers? Yoram Cohen M.D. Department of Obstetrics and Gynecology, IVF Unit, Sheba
More informationHuman leukocyte antigen-b27 alleles in Xinjiang Uygur patients with ankylosing spondylitis
Human leukocyte antigen-b27 alleles in Xinjiang Uygur patients with ankylosing spondylitis H.-Y. Zou, W.-Z. Yu, Z. Wang, J. He and M. Jiao Institute of Clinical Medicine, Urumqi General Hospital, Lanzhou
More informationOriginal articles. Fragile X syndrome is previously estimated. less common than. giving rise to an overall prevalence
JMed Genet 1997;34:1-5 Original articles I Clinical Genetics Unit, Birmingham Women's Hospital, Edgbaston, Birmingham B15 2TG, J E Morton Department of Clinical Genetics, University of Birmingham, Birmingham
More informationAutistic Behavior, FMR1 Protein, and Developmental Trajectories in Young Males with Fragile X Syndrome
Journal of Autism and Developmental Disorders, Vol. 31, No. 2, 2001 Autistic Behavior, FMR1 Protein, and Developmental Trajectories in Young Males with Fragile X Syndrome Donald B. Bailey, Jr., 1 Deborah
More informationThe Fragile X-Associated Tremor Ataxia Syndrome (FXTAS) READ ONLINE
The Fragile X-Associated Tremor Ataxia Syndrome (FXTAS) READ ONLINE If you are searching for a ebook The Fragile X-Associated Tremor Ataxia Syndrome (FXTAS) in pdf form, then you have come on to correct
More informationapproach Population studies of the fragile X: a molecular ORIGINAL ARTICLES
454 Med Genet 1993; 30: 454-459 ORIGINAL ARTICLES Wessex Regional Genetics Laboratory, Salisbury District Hospital, Odstock, Salisbury SP2 8BJ, UK. P A Jacobs H Bullman J Macpherson S Youings Community
More informationMOLECULAR DIAGNOSIS for X-LINKED INTELLECTUAL DISABILITY
MOLECULAR DIAGNOSIS for X-LINKED INTELLECTUAL DISABILITY Intellectual disability (ID) or mental retardation is characterized by significant limitations in cognitive abilities and social/behavioral adaptive
More informationP renatal Diag nosis of F rag ile X S yndrom e u sing Amn iotic F luid DNA
44 3 2001 Vol. 44 No. 3 March 2001 DNA X, * * =ABSTRACT= P renatal Diag nosis of F rag ile X S yndrom e u sing Amn iotic F luid DNA Gwan g J u n Kim, Su k You n g Kim, Byu n g Ch eu l Hwan g, Ch an You
More informationMRC-Holland MLPA. Description version 08; 30 March 2015
SALSA MLPA probemix P351-C1 / P352-D1 PKD1-PKD2 P351-C1 lot C1-0914: as compared to the previous version B2 lot B2-0511 one target probe has been removed and three reference probes have been replaced.
More informationThis fact sheet describes the condition Fragile X and includes a discussion of the symptoms, causes and available testing.
11111 Fact Sheet 54 FRAGILE X SYNDROME This fact sheet describes the condition Fragile X and includes a discussion of the symptoms, causes and available testing. In summary Fragile X is a condition caused
More informationFragile X full mutation expansions are inhibited by one or more AGG interruptions in premutation carriers
American College of Medical Genetics and Genomics Original Research Article Open Fragile X full mutation expansions are inhibited by one or more AGG interruptions in premutation carriers Sarah L. Nolin,
More informationMMB (MGPG) Non traditional Inheritance Epigenetics. A.Turco
MMB (MGPG) 2017 Non traditional Inheritance Epigenetics A.Turco NON TRADITIONAL INHERITANCE EXCEPTIONS TO MENDELISM - Genetic linkage (2 loci close to each other) - Complex or Multifactorial Disease (MFD)
More informationTEST INFORMATION Test: CarrierMap GEN (Genotyping) Panel: CarrierMap Expanded Diseases Tested: 311 Genes Tested: 299 Mutations Tested: 2647
Ordering Practice Jane Smith John Smith Practice Code: 675 Miller MD 374 Broadway New York, NY 10000 Physician: Dr. Frank Miller Report Generated: 2016-02-03 DOB: 1973-02-19 Gender: Female Ethnicity: European
More informationProduct Datasheet. DARC Antibody NB Unit Size: 0.1 mg. Store at -20C. Avoid freeze-thaw cycles. Publications: 5
Product Datasheet DARC Antibody NB100-2421 Unit Size: 0.1 mg Store at -20C. Avoid freeze-thaw cycles. Publications: 5 Protocols, Publications, Related Products, Reviews, Research Tools and Images at: www.novusbio.com/nb100-2421
More informationSesh Kamal Sunkara Aberdeen Fertility Centre Aberdeen Maternity Hospital University of Aberdeen Aberdeen, UK
Sesh Kamal Sunkara Aberdeen Fertility Centre Aberdeen Maternity Hospital University of Aberdeen Aberdeen, UK Declared no potential conflict of interest Genetic aetiology of poor and hyper responders Sesh
More informationCytogenetic Diagnosis of Fragile X Syndrome: Study of 305 Suspected Cases in Saudi Arabia
Cytogenetic Diagnosis of Fragile X Syndrome: Study of 305 Suspected Cases in Saudi Arabia M. Anwar Iqbal, PhD, FACMG; Nadia Sakati, MD; Michael Nester, PhD; Pinar Ozand, MD, PhD From the Departments of
More informationNew: P077 BRCA2. This new probemix can be used to confirm results obtained with P045 BRCA2 probemix.
SALSA MLPA KIT P045-B2 BRCA2/CHEK2 Lot 0410, 0609. As compared to version B1, four reference probes have been replaced and extra control fragments at 100 and 105 nt (X/Y specific) have been included. New:
More informationProduct Datasheet. CD133 Antibody NB Unit Size: 0.1 mg
Product Datasheet CD133 Antibody NB120-16518 Unit Size: 0.1 mg Store at 4C short term. Aliquot and store at -20C long term. Avoid freeze-thaw cycles. Publications: 8 Protocols, Publications, Related Products,
More informationExperts call for universal fragile X screening
NEWS Experts call for universal fragile X screening BY ANDREA ANDERSON 1 APRIL 2008 1 / 5 Clean sweep: Universal screening would detect even asymptomatic carriers of fragile X. Screening for genetic precursors
More informationEVOLVE FERTILITY GENETIC SCREENS
LEADERS IN GENETIC FERTILITY SCREENING TM FOR MEN & WOMEN EVOLVE FERTILITY GENETIC SCREENS The most advanced and comprehensive fertility genetic screens on the market today. SCREEN TODAY. PROTECT TOMORROW.
More informationFragile X Syndrome and Infertility Case Example - Not One, but Three
Vol. 008 Fragile X Syndrome and Infertility Fragile X Syndrome and Infertility Case Example - Not One, but Three Abstract A case review of a female patient who was treated for infertility of unknown reasons
More informationFragile X syndrome, caused by mutations in a
The Influence of Environmental and Genetic Factors on Behavior Problems and Autistic Symptoms in Boys and Girls With Fragile X Syndrome David Hessl, PhD*; Jennifer Dyer-Friedman, PhD*; Bronwyn Glaser,
More informationMRC-Holland MLPA. Description version 08; 18 November 2016
SALSA MLPA probemix P122-D1 NF1 AREA Lot D1-1016. As compared to lot C2-0312, four probes in the NF1 area and one reference probe have been removed, four reference probes have been replaced and several
More informationCorporate Medical Policy
Corporate Medical Policy Genetic Testing for FMR1 Mutations Including Fragile X Syndrome File Name: Origination: Last CAP Review Next CAP Review Last Review genetic_testing_for_fmr1_mutations_including_fragile_x_syndrome
More informationEVOLVE GENETIC FERTILITY SCREENS
LEADERS IN GENETIC FERTILITY SCREENING TM FOR MEN & WOMEN EVOLVE GENETIC FERTILITY SCREENS The most advanced and comprehensive pre-ivf fertility screens on the market today. SCREEN TODAY. PROTECT TOMORROW.
More informationFRAGILE X-ASSOCIATED TREMOR/ATAXIA SYNDROME (FXTAS)
FRAGILE X CLINICAL & RESEARCH CONSORTIUM Consensus of the FXTAS Task Force and the Fragile X Clinical & Research Consortium FRAGILE X-ASSOCIATED TREMOR/ATAXIA SYNDROME (FXTAS) First Published: June 2011
More informationMolecular and imaging correlates of the fragile X associated tremor/ ataxia syndrome
Molecular and imaging correlates of the fragile X associated tremor/ ataxia syndrome S. Cohen, MS; K. Masyn, PhD; J. Adams, BA; D. Hessl, PhD; S. Rivera, PhD; F. Tassone, PhD; J. Brunberg, MD; C. DeCarli,
More informationSoluble ADAM33 initiates airway remodeling to promote susceptibility for. Elizabeth R. Davies, Joanne F.C. Kelly, Peter H. Howarth, David I Wilson,
Revised Suppl. Data: Soluble ADAM33 1 Soluble ADAM33 initiates airway remodeling to promote susceptibility for allergic asthma in early life Elizabeth R. Davies, Joanne F.C. Kelly, Peter H. Howarth, David
More information+ Fragile X Tremor Ataxia Syndrome (FXTAS)
+ Fragile X Tremor Ataxia Syndrome (FXTAS) Le point de vue du neurologue n Gaëtan Garraux n CHU de Liège n www.movere.org + Background FXTAS was first described by Hagerman and coll. (2001) as they collected
More informationMRC-Holland MLPA. Description version 29;
SALSA MLPA KIT P003-B1 MLH1/MSH2 Lot 1209, 0109. As compared to the previous lots 0307 and 1006, one MLH1 probe (exon 19) and four MSH2 probes have been replaced. In addition, one extra MSH2 exon 1 probe,
More informationEukaryotic Gene Regulation
Eukaryotic Gene Regulation Chapter 19: Control of Eukaryotic Genome The BIG Questions How are genes turned on & off in eukaryotes? How do cells with the same genes differentiate to perform completely different,
More informationFamilial Mental Retardation
Behavior Genetics, Vol. 14, No. 3, 1984 Familial Mental Retardation Paul L. Nichols ~ Received 18 Aug. 1983--Final 2 Feb. 1984 Familial patterns of mental retardation were examined among white and black
More informationIdentification of a novel in-frame de novo mutation in SPTAN1 in intellectual disability and pontocerebellar atrophy
Hamdan et al., Identification of a novel in-frame de novo mutation in SPTAN1 in intellectual disability and pontocerebellar atrophy Supplementary Information Gene screening and bioinformatics PCR primers
More informationSALSA MLPA probemix P241-D2 MODY mix 1 Lot D As compared to version D1 (lot D1-0911), one reference probe has been replaced.
mix P241-D2 MODY mix 1 Lot D2-0413. As compared to version D1 (lot D1-0911), one reference has been replaced. Maturity-Onset Diabetes of the Young (MODY) is a distinct form of non insulin-dependent diabetes
More informationTitle: Development and validation of a multiplex-pcr assay for X-linked intellectual disability
Author's response to reviews Title: Development and validation of a multiplex-pcr assay for X-linked intellectual disability Authors: PAULA JORGE (paula.jorge@insa.min-saude.pt) Bárbara Oliveira (barbara.oliveira@insa.min-saude.pt)
More informationProduct Datasheet. HLA ABC Antibody (W6/32) NB Unit Size: 0.25 mg. Store at -20C. Avoid freeze-thaw cycles. Reviews: 1 Publications: 22
Product Datasheet HLA ABC Antibody (W6/32) NB100-64775 Unit Size: 0.25 mg Store at -20C. Avoid freeze-thaw cycles. Reviews: 1 Publications: 22 Protocols, Publications, Related Products, Reviews, Research
More informationFeatures of Developmental Functions and Autistic Profiles in Children with Fragile X Syndrome
Original Article 551 Features of Developmental Functions and Autistic Profiles in Children with Fragile Syndrome Jyh-Yuh Ke, MD; Chia-Ling Chen, MD, PhD; Ying-Jing Chen 1, MD; Chia-Hui Chen, MD; Li-Fang
More informationFragile X syndrome prenatal diagnosis: parental attitudes and reproductive responses
Reproductive BioMedicine Online (2010) 21, 560 565 www.sciencedirect.com www.rbmonline.com ARTICLE Fragile X syndrome prenatal diagnosis: parental attitudes and reproductive responses M Xunclà a,b, C Badenas
More informationMRC-Holland MLPA. Description version 29; 31 July 2015
SALSA MLPA probemix P081-C1/P082-C1 NF1 P081 Lot C1-0114. As compared to the previous B2 version (lot 0813 and 0912), 11 target probes are replaced or added, and 10 new reference probes are included. P082
More informationNature Structural & Molecular Biology: doi: /nsmb Supplementary Figure 1. Generation and validation of mtef4-knockout mice.
Supplementary Figure 1 Generation and validation of mtef4-knockout mice. (a) Alignment of EF4 (E. coli) with mouse, yeast and human EF4. (b) Domain structures of mouse mtef4 compared to those of EF4 (E.
More informationThe Nottingham eprints service makes this work by researchers of the University of Nottingham available open access under the following conditions.
Stöger, Reinhard and Genereux, Diane P. and Hagerman, Randi J. and Hagerman, Paul J. and Tassone, Flora and Laird, Charles D. (2011) Testing the FMR1 promoter for mosaicism in DNA methylation among CpG
More informationProduct Datasheet. IGF-I R Antibody (3G5C1) NB Unit Size: 0.1 ml
Product Datasheet IGF-I R Antibody (3G5C1) NB110-87052 Unit Size: 0.1 ml Store at 4C short term. Aliquot and store at -20C long term. Avoid freeze-thaw cycles. Reviews: 2 Publications: 8 Protocols, Publications,
More informationCURRENT GENETIC TESTING TOOLS IN NEONATAL MEDICINE. Dr. Bahar Naghavi
2 CURRENT GENETIC TESTING TOOLS IN NEONATAL MEDICINE Dr. Bahar Naghavi Assistant professor of Basic Science Department, Shahid Beheshti University of Medical Sciences, Tehran,Iran 3 Introduction Over 4000
More informationMOLECULAR DIAGNOSIS for X-LINKED INTELLECTUAL DISABILITY
MOLECULAR DIAGNOSIS for X-LINKED INTELLECTUAL DISABILITY WHAT IS X-LINKED INTELLECTUAL DISABILITY? Intellectual disability (ID), sometimes called mental retardation (MR) or developmental delay (DD), is
More informationDifferentiation-induced Changes of Mediterranean Fever Gene (MEFV) Expression in HL-60 Cell
Differentiation-induced Changes of Mediterranean Fever Gene (MEFV) Expression in HL-60 Cell Wenxin Li Department of Biological Sciences Fordham University Abstract MEFV is a human gene that codes for an
More informationKim M. Cornish, PhD* Darren R. Hocking, PhD* Simon A. Moss, PhD Cary S. Kogan, PhD
ARTICLES Selective executive markers of at-risk profiles associated with the fragile X premutation Kim M. Cornish, PhD* Darren R. Hocking, PhD* Simon A. Moss, PhD Cary S. Kogan, PhD Address correspondence
More informationAssessing the Fragile X Syndrome Newborn Screening Landscape Catharine Riley, PhD, MPH, a Anne Wheeler, PhD b
Assessing the Fragile X Syndrome Newborn Screening Landscape Catharine Riley, PhD, MPH, a Anne Wheeler, PhD b BACKGROUND: Fragile X syndrome (FXS) is the most common known inherited form of intellectual
More informationProtein MultiColor Stable, Low Range
Product Name: DynaMarker Protein MultiColor Stable, Low Range Code No: DM670L Lot No: ******* Size: 200 μl x 3 (DM670 x 3) (120 mini-gel lanes) Storage: 4 C Stability: 12 months at 4 C Storage Buffer:
More informationDownregulation of serum mir-17 and mir-106b levels in gastric cancer and benign gastric diseases
Brief Communication Downregulation of serum mir-17 and mir-106b levels in gastric cancer and benign gastric diseases Qinghai Zeng 1 *, Cuihong Jin 2 *, Wenhang Chen 2, Fang Xia 3, Qi Wang 3, Fan Fan 4,
More informationSupplemental Figure 1 ELISA scheme to measure plasma total, mature and furin-cleaved
1 Supplemental Figure Legends Supplemental Figure 1 ELISA scheme to measure plasma total, mature and furin-cleaved PCSK9 concentrations. 4 Plasma mature and furin-cleaved PCSK9s were measured by a sandwich
More informationSALSA MLPA probemix P241-D2 MODY mix 1 Lot D2-0716, D As compared to version D1 (lot D1-0911), one reference probe has been replaced.
mix P241-D2 MODY mix 1 Lot D2-0716, D2-0413. As compared to version D1 (lot D1-0911), one reference has been replaced. Maturity-Onset Diabetes of the Young (MODY) is a distinct form of non insulin-dependent
More informationMRC-Holland MLPA. Description version 07; 26 November 2015
SALSA MLPA probemix P266-B1 CLCNKB Lot B1-0415, B1-0911. As compared to version A1 (lot A1-0908), one target probe for CLCNKB (exon 11) has been replaced. In addition, one reference probe has been replaced
More informationA complete next-generation sequencing workfl ow for circulating cell-free DNA isolation and analysis
APPLICATION NOTE Cell-Free DNA Isolation Kit A complete next-generation sequencing workfl ow for circulating cell-free DNA isolation and analysis Abstract Circulating cell-free DNA (cfdna) has been shown
More informationADVANCED PGT SERVICES
Genomic Prediction ADVANCED PGT SERVICES with PGT-A using SEQ is a cost-effective, rigorously validated, unambiguous, and streamlined test for aneuploidy in blastocyst biopsies, and uses state of the art
More informationSupporting Information Table of Contents
Supporting Information Table of Contents Supporting Information Figure 1 Page 2 Supporting Information Figure 2 Page 4 Supporting Information Figure 3 Page 5 Supporting Information Figure 4 Page 6 Supporting
More informationIso-Seq Method Updates and Target Enrichment Without Amplification for SMRT Sequencing
Iso-Seq Method Updates and Target Enrichment Without Amplification for SMRT Sequencing PacBio Americas User Group Meeting Sample Prep Workshop June.27.2017 Tyson Clark, Ph.D. For Research Use Only. Not
More informationMRC-Holland MLPA. Description version 30; 06 June 2017
SALSA MLPA probemix P081-C1/P082-C1 NF1 P081 Lot C1-0517, C1-0114. As compared to the previous B2 version (lot B2-0813, B2-0912), 11 target probes are replaced or added, and 10 new reference probes are
More informationIntroduction to Genetics
Introduction to Genetics Table of contents Chromosome DNA Protein synthesis Mutation Genetic disorder Relationship between genes and cancer Genetic testing Technical concern 2 All living organisms consist
More informationINVESTIGATION THE PREVALENCE OF MUTATIONS IVS 10 AND R158Q IN A NUMBER OF IRANIAN PATIENTS WITH PKU
: 293-297 ISSN: 2277 4998 INVESTIGATION THE PREVALENCE OF MUTATIONS IVS 10 AND R158Q IN A NUMBER OF IRANIAN PATIENTS WITH PKU SHIRIN JAHANBAZI, FATEMEHKESHAVARZI* Department of Biology, Sanandaj Branch,
More informationMRC-Holland MLPA. Description version 14; 28 September 2016
SALSA MLPA probemix P279-B3 CACNA1A Lot B3-0816. As compared to version B2 (lot B2-1012), one reference probe has been replaced and the length of several probes has been adjusted. Voltage-dependent calcium
More informationCHAPTER 1 INTRODUCTION
1 CHAPTER 1 INTRODUCTION 1.1. BACKGROUND Fragile X mental retardation 1 gene (FMR1) is located on the X chromosome and is responsible for producing the fragile X mental retardation protein (FMRP) which
More informationJOURNAL OF CLINICAL AND DIAGNOSTIC RESEARCH
JOURNAL OF CLINICAL AND DIAGNOSTIC RESEARCH How to cite this article: DAS B, DUTTA S, CHATTERJEE A, SINHA S, CHATTOPADHYAY A, MUKHOPADHYAY KANCHAN.SCREENING FOR FRAGILE X SYNDROME AMONG NEUROBEHAVIOURAL
More informationAmbient Temperature Stabilization of RNA derived from Jurkat, HeLa and HUVEC Cell Lines for Use in RT-qPCR Assays
Ambient Temperature Stabilization of RNA derived from Jurkat, HeLa and HUVEC Cell Lines for Use in RT-qPCR Assays C. Litterst 1, H. Martinez, B. Iverson and R. Nuňez 1 Bio-Rad Laboratories, Life Science
More informationFunding: NIDCF UL1 DE019583, NIA RL1 AG032119, NINDS RL1 NS062412, NIDA TL1 DA
The Effect of Cognitive Functioning, Age, and Molecular Variables on Brain Structure Among Carriers of the Fragile X Premutation: Deformation Based Morphometry Study Naomi J. Goodrich-Hunsaker*, Ling M.
More informationContraction of a Maternal Fragile X Mental Retardation 1 Premutation Allele
Elmer ress Case Report J Med Cases. 2015;6(12):547-553 Contraction of a Maternal Fragile X Mental Retardation 1 Premutation Allele Patricia Miranda a, Poonnada Jiraanont a, b, Liane J. Abrams c, Kirin
More informationYork criteria, 6 RA patients and 10 age- and gender-matched healthy controls (HCs).
MATERIALS AND METHODS Study population Blood samples were obtained from 15 patients with AS fulfilling the modified New York criteria, 6 RA patients and 10 age- and gender-matched healthy controls (HCs).
More informationMicroRNA sponges: competitive inhibitors of small RNAs in mammalian cells
MicroRNA sponges: competitive inhibitors of small RNAs in mammalian cells Margaret S Ebert, Joel R Neilson & Phillip A Sharp Supplementary figures and text: Supplementary Figure 1. Effect of sponges on
More informationMouse Leptin ELISA Kit (mleptin-elisa)
Mouse Leptin ELISA Kit (mleptin-elisa) Cat. No. EK0438 96 Tests in 8 x 12 divisible strips Background Leptin (or obese, OB) is a circulating hormone that is expressed abundantly and specifically in the
More informationPrevalence of Fragile X syndrome among children receiving special education and carrier states in first degree relatives
Prevalence of Fragile X syndrome among children receiving special education and carrier states in first degree relatives B Chandrasekara 1, S Wijesundera 1, S S Chong 2,3,4, H N Perera 5 (Index words:
More information2018 Gatlinburg Conference Symposium Submission SS 6
Symposium Title: Stress, Risk, and Resiliency for Women with a FMR1 Premutation Chair: Anne C. Wheeler 1 and Jessica Klusek 2 Discussant: Marsha Mailick 3 Overview: Accumulating evidence suggest that FMR1
More information